Document 0559
 DOCN  M9610559
 TI    Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen
       given together with a novel muramyl dipeptide adjuvant,
       N-acetyl-D-glucosaminyl-(beta
       1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
 DT    9601
 AU    Hornung RL; Longo DL; Gowda VL; Kwak LW; Biological Carcinogenesis &
       Development Program, Program; Resources, Inc./DynCorp, Frederick, MD,
       USA.
 SO    Ther Immunol. 1995 Feb;2(1):7-14. Unique Identifier : AIDSLINE
       MED/96002631
 AB    We have investigated the ability of the novel muramyl dipeptide, GMDP,
       to act as an adjuvant for the induction of ovalbumin (OVA)-specific,
       CD8+ cytotoxic T lymphocyte (CTL) responses. C57Bl/6 mice were twice
       immunized s.c. with 50 micrograms OVA emulsified with a squalane, L121
       pluronic containing Tween-80 vehicle either with (STP-GMDP) or without
       (STP) GMDP. Splenic precursor CD8+ CTL activity against E.G7-OVA, but
       not against EL-4 parental targets was detected in STP-GMDP immunized
       mice after 5 days of in vitro re-stimulation with irradiated E.G7-OVA
       cells, while mice immunized with OVA in STP alone or OVA alone failed to
       demonstrate CTL activity. OVA emulsified in a microfluidized STP vehicle
       formulation without GMDP also elicited the E.G7-OVA precursor CTL. The
       ability of GMDP to induce a class I-restricted, CD8+ CTL response to a
       soluble protein antigen may have implications for the development of
       useful vaccines against viral pathogens or tumours against which CTL
       responses are desirable.
 DE    Acetylmuramyl-Alanyl-Isoglutamine/*ANALOGS & DERIVATIVES/
       ADMINISTRATION & DOSAGE  Adjuvants, Immunologic/*ADMINISTRATION & DOSAGE
       Animal  Antigens/*ADMINISTRATION & DOSAGE  *Cytotoxicity, Immunologic
       CD8-Positive T-Lymphocytes/*IMMUNOLOGY  Female  Immunization  In Vitro
       Mice  Mice, Inbred C57BL  Ovalbumin/IMMUNOLOGY  Solubility  Tumor Cells,
       Cultured  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).